Assessment of the Effect of Multidrug Resistance Clostridium difficile Clinical Strains on the Dynamics of Clostridium difficile Infection Rate at Pediatric Oncological Hospital

Relevance. At the children's oncological hospital guidelines to treat patients with several groups of antibiotics at the same time, which ensures the formation of multi-resistant strains of Clostridium difficile, which have a selective advantage for the Clostridium difficile infection developing, and also cause epidemics and /or in associating with an increase in the severity of Clostridium difficile – infection.

Aims. Multidrug resistance Clostridium difficile strains and Clostridium difficile infection rate at pediatric oncological hospital.

Results. An investigation of the Clostridium difficile resistance strains carried out among children at the children's oncological hospital. 143 toxigenic strains are resistant to moxifloxacin 72.41%, clindamycin 63.72%, rifampicin 35.54%, tetracycline 26.45%, tigecycline 11.42%, vancomycin 4.4%, metronidazole 3.9%. At the same time, the increase multidrug-resistant strains proportion note at the level of 3–4% per year. However, the rate of Clostridium difficile infection among children at the oncological hospital remained at the level of 0.4% to 3.1% with a downward trend. As a result, statistical calculations showed the absence of correlation between multidrug resistance and morbidity.

Conclusions. Detection of multidrug-resistant microorganisms among toxigenic Clostridium difficile strains proves the need for further study of this problem in Russia and the advisability of monitoring Clostridium difficile infection rate and multidrug resistance Clostridium difficile strains at pediatric oncological hospitals.

1. Saavedra PHV, Huang L, Ghazavi F, et al. Apoptosis of intestinal epithelial cells restricts Clostridium difficile infection in a model of pseudomembranous colitis. Nature Communications. 2018;9:48–46. doi: 10.1038/s41467-018-07386-5.

2. McFarland L V, Ozen M, Dinleyici EC, et al. Comparison of pediatric and adult antibiotic-associated diarrhea and Clostridium difficile infections. World Journal of Gastroenterology. 2016;22(11):3078–3104. doi: 10.3748/wjg.v22.i11.3078.

3. Vindigni SM, Surawicz CM. C. difficile Infection: Changing Epidemiology and Management Paradigms. Clinical and Translational Gastroenterology. 2015;6(7):e99. doi: 10.1038/ctg.2015.24.

4. Lynch T, Chong P, Zhang J, et al. Characterization of a Stable, Metronidazole-Resistant Clostridium Difficile Clinical Isolate. PLoS One. 2013;8(1):e53757. doi: 10.1371/journal. pone.0053757.

5. Gonchar NV, Lazareva IV, Rychkova SV, et al. Zabolevayemost’ detey sal’monellezom i uroven’ rezistentnosti klinicheskikh shtammov sal’monell k antibakterial’nym preparatam v Sankt-Peterburge. Zhurnal infektologii. 2015;7(1):80–86. (In Russ).

6. Erikstrup LT, Danielsen TK, Hall V, et al. Antimicrobial susceptibility testing of Clostridium difficile using EUCAST epidemiological cut-off values and disk diffusion correlates. Clin Microbiol Infect. 2012;18(8):E266-E272. doi:10.1111/j.1469-0691.2012.03907x.

7. Fraga EG, Nicodemo AC, Sampaio JLM, et al. Antimicrobial susceptibility of Brazilian Clostridium difficile strains determined by agar dilution and disk diffusion //The Brazilian Journal of Infectious Diseases. 2016. Vol. 20, №5. P. 476–81. doi: 10.1016/j.bjid.2016.07.004.

8. Rupnik M., Wilcox M.H., Gerding D.N. Clostridium difficile infection: new developments in epidemiology and pathogenesis. //Nature Reviews Microbiology. 2009. Vol. 7, №7. P. 526–36. doi: 10.1038/nrmicro2164.

9. Isidro J, Mendes AL, Serrano M,, et al. Overview of Clostridium difficile Infection: Life Cycle, Epidemiology, Antimicrobial Resistance and Treatment. Clostridium Difficile A Comprehensive Overview. Immunology and Microbiology. 2017. Available at: https://www.intechopen.com/books/clostridium-difficile-a-comprehensive-overview/over-view-of-clostridium-difficile-infection-life-cycle-epidemiology-antimicrobial-resistance-and-tre Accessed: 26 Aug 2020.

10. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria; Eighth Edition. CLSI document M11-A8. Wayne, PA: Clinical and Laboratory Standard Institute. 2012. Available at: https://clsi.org/media/1468/m11a8_sample.pdf Accessed: 26 Aug 2020.

11. Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0. The European Committee on Antimicrobial Susceptibility Testing. 2020. Available at: https://www.eucast.org/clinical_breakpoints/ Accessed: 26 Aug 2020.

12. Gateau C., Couturier J., Coia J., et al. How to: diagnose infection caused by Clostridium difficile //Clinical Microbiology and Infection. 2018. Vol. 24, №5. P. 463–468. doi: 10.1016/j.cmi.2017.12.005.

13. Spigaglia P., Recent advances in the understanding of antibiotic resistance in Clostridium difficile infection //Therapeutic advances in infection desease. 2016. Vol. 3, №1. P. 23–42. doi: 10.1177/2049936115622891.

14. Banawas S. S. Clostridium difficile Infections: A Global Overview of Drug Sensitivity and Resistance Mechanisms //BioMed Research International. 2018. Vol. 2018. P. 1–9. doi: 10.1155/2018/8414257.

15. Magiorakos A.-P., Srinivasan A., Carey R. B., et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. //Clin Microbiol Infect. 2012; Vol. 18, P. 268–281

16. Cohen S.H., Gerding D.N., Johnson S., et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). //Infection Control Hospital Epidemiology. 2010. Vol. 31, №5. P. 431–455. doi: https://doi.org/10.1086/651706.

17. Freeman, J., Vernon, J., Pilling, S., et al. Five-year Pan-European, longitudinal surveillance of Clostridium difficile ribotype prevalence and antimicrobial resistance: the extended ClosER study //Eur J Clin Microbiol Infect Dis. 2020. Vol. 39, P. 169–177. https://doi.org/10.1007/s10096-019-03708-7.

18. Tkhawkho L., Nitzan O., Pastukh N., et al. Antimicrobial susceptibility of Clostridium difficile isolates in Israel //Journal of Global Antimicrobial Resistance. 2017. Vol. 10. P. 161–164 doi: 10.1016/j.jgar.2017.04.005.

19. Goudarzi M., Goudarzi H., Alebouyeh M., et al. Antimicrobial Susceptibility of Clostridium Difficile Clinical Isolates in Iran. //Iranian Red Crescent Medical Journal. 2013. Vol. 15, №8. P.704–711 doi: 10.5812/ircmj.5189.

20. Salamonowicz, M., Ociepa, T., Frączkiewicz, J., et al. Incidence, course, and outcome of Clostridium difficile infection in children with hematological malignancies or undergoing hematopoietic stem cell transplantation. //Eur J Clin Microbiol Infect Dis. 2018. Vol. 37, P. 1805–1812. https://doi.org/10.1007/s10096-018-3316-5.